Page 1

HENRY SCHEIN SOLUTIONS FOR HEALTH CARE PROFESSIONALS Henry Schein Reports Record Second - Quarter 2021 Financial Results From Continuing Operations August 3 , 2021 • Total net sales of $ 3.0 billion up 76.2 % versus prior year and up 21.2 % versus 2019 • GAAP diluted EPS from continuing operations of $ 1.10 versus prior - year GAAP loss per diluted share from continuing operations of $ 0.08 • Non - GAAP diluted EPS from continuing operations of $ 1.11 versus prior - year non - GAAP diluted EPS from continuing operations of $ 0.00 • Reflecting strong first - half financial results , raises guidance for 2021 non - GAAP diluted EPS from continuing operations to be at or above $ 3.85 , representing a floor for fiscal 2021 MELVILLE , N.Y .-- ( BUSINESS WIRE ) -- Aug . 3 , 2021-- Henry Schein , Inc. ( Nasdaq : HSIC ) , the world's largest provider of health care solutions to office - based dental and medical practitioners , today reported record second - quarter financial results from continuing operations . Results from continuing operations exclude contributions from Henry Schein's former Animal Health business , which was spun off in February 2019 to form a new publicly traded company , Covetrus ( Nasdaq : CVET ) . Total net sales for the quarter ended June 26 , 2021 , were $ 3.0 billion , up 76.2 % compared with the second quarter of 2020 , when a significant number of dental and medical practices suspended activity because of the COVID - 19 pandemic . The 76.2 % increase included 65.5 % internal growth in local currencies , 5.5 % growth from acquisitions and 5.2 % growth related to foreign currency exchange . When compared with the pre - pandemic second quarter of 2019 , sales were up 21.2 % and included 15.2 % internal growth in local currencies , 4.2 % growth from acquisitions and 1.8 % growth related to foreign currency exchange . Exhibit A provides details of sales growth , including comparisons with 2020. Note that Exhibit A - 1 contains details of sales performance compared with 2019 . GAAP net income attributable to Henry Schein , Inc. from continuing operations for the second quarter of 2021 was $ 155.7 million , or $ 1.10 per diluted share , compared with prior - year GAAP net loss from continuing operations of $ 11.4 million , or $ 0.08 per diluted share . Non - GAAP net income from continuing operations for the second quarter of 2021 was $ 157.3 million , or $ 1.11 per diluted share , compared with prior - year non - GAAP net income from continuing operations of $ 0.6 million , or $ 0.00 per diluted share . Exhibit B provides a reconciliation of GAAP net income and diluted EPS from continuing operations to non - GAAP net income and diluted EPS from continuing operations . " We are pleased to report record second - quarter financial results as we continue to execute on our key strategies . Strengthening demand in the global dental and medical markets drove strong year - over - year increases in sales versus the prior year when many of our customers had temporarily closed their offices . Notably , compared with a pre - COVID - 19 environment in the second quarter of 2019 , Henry Schein's worldwide internal sales in local currencies increased by 15.2 % , " said Stanley M. Bergman , Chairman of the Board and Chief Executive Officer of Henry Schein . " We are also pleased with operating margin expansion that reflects a favorable product mix as well as operating expense leverage . " Mr. Bergman continued , " With solid execution in the first half of 2021 and a favorable outlook for the remainder of the fiscal year , we are raising our guidance for 2021 non - GAAP diluted EPS from continuing operations to be at or above $ 3.85 , representing a floor for fiscal 2021. We will continue to monitor any potential impact to our business as a result of COVID - 19 . " Global Dental sales for the second quarter of 2021 of $ 1.9 billion increased 102.9 % versus the prior - year period . In local currencies , internally generated sales increased 87.0 % with 7.3 % growth from acquisitions and 8.6 % growth related to foreign currency exchange . The 87.0 % internal growth in local currencies included an increase of 105.3 % in North America and an increase of 64.9 % internationally . Global Dental consumable merchandise internal sales increased 90.5 % in local currencies . Excluding sales of personal protective equipment ( PPE ) and COVID - 19 related products , growth was 96.2 % . In North America , dental consumable merchandise internal sales in local currencies increased 112.5 % , or 119.1 % excluding sales of PPE and COVID - 19 related products , and dental equipment internal sales in local currencies increased 82.0 % . Internationally , dental consumable merchandise internal sales in local currencies increased 64.4 % , or 70.2 % excluding sales of PPE and COVID - 19 related products , and dental equipment internal sales in local currencies increased 66.6 % . " Global dental sales experienced strong growth , with gains in both consumable merchandise and equipment . More specifically , consumable merchandise sales in North America and in our international markets experienced double - digit growth versus the same period in 2019 , " noted Mr. Bergman . " Compared with the second quarter of 2019 , North America dental equipment sales growth was modest , primarily reflecting delays with certain U.S. manufacturers of chairs , units , and lights , resulting in longer lead times . We reported strong equipment growth in our international markets with no significant delays . Our overall dental sales performance reflects a continued recovery in patient traffic compared to pre - pandemic levels , and we remain optimistic about dental practices investing in technology and equipment over the long term . " Global Medical sales for the second quarter of 2021 of $ 904.8 million increased 46.5 % versus the comparable period last year , consisting of 43.5 % internal growth in local currencies , 2.6 % growth from acquisitions and 0.4 % growth related to foreign currency exchange . Excluding sales of PPE and COVID - 19 related products , internal sales in local currencies increased 39.1 % . " We believe our medical sales continued to outpace end - market performance with broad - based growth versus the same period in 2019 , including growth in medical - surgical , equipment , and laboratory product sales . We continue to expand our medical business beyond core distribution with a differentiated solutions offering that serves low acuity segments of the market , which is the most cost - efficient setting for delivering care , " remarked Mr. Bergman . Global Technology and Value - Added Services sales of $ 152.1 million increased 44.5 % versus the prior - year quarter and included 33.0 % internal sales growth in local currencies , 8.9 % growth from acquisitions and 2.6 % growth related to foreign currency exchange .